A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4 T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease
Melinda Y Hardy, Gautam Goel, Amy K Russell, Swee Lin G Chen Yi Mei, Gregor JE Brown, Suyue Wang, Evan Szymczak, Ruan Zhang, Kaela E Goldstein, Kristin M Neff, Leslie J Williams, Kenneth E Truitt, John L Dzuris, Jason A Tye-Din, Robert P Anderson
FRONTIERS IN IMMUNOLOGY | FRONTIERS MEDIA SA | Published : 2021
Improved blood tests assessing the functional status of rare gluten-specific CD4+ T cells are needed to effectively monitor experimental therapies for coeliac disease (CD). Our aim was to develop a simple, but highly sensitive cytokine release assay (CRA) for gluten-specific CD4+ T cells that did not require patients to undergo a prior gluten challenge, and would be practical in large, multi-centre clinical trials. We developed an enhanced CRA and used it in a phase 2 clinical trial ("RESET CeD") of Nexvax2, a peptide-based immunotherapy for CD. Two participants with treated CD were assessed in a pilot study prior to and six days after a 3-day gluten challenge. Dye-dilution proliferation in ..View full abstract
Awarded by NHMRC
Funding for this work was provided by ImmusanT, Inc., Cambridge, Massachusetts USA. JT-D and his team (AR, MH) were supported by theNHMRC(APP1176553), the University of Melbourne (Mathison Centenary Fellowship), the Beck Family Foundation and Coeliac Australia.